×

Supplier Summit & Awards 2023, Bangalore

Stakeholder engagement

The Company recognizes the important role that stakeholders play in sustaining future growth. Through regular interactions and strategic engagements, we aim to build relationships that enable us to pursue sustained business growth with support and alignment of all stakeholders.27

Key Stakeholders

Stakeholder Channel for communication Nature of communication

CSR partners

The Company’s CSR programs are overseen by the Biocon Foundation, which serves as the CSR arm of the Biocon Group. The Company also directly collaborates with agencies and institutions to carry out its CSR initiatives.

Biocon Foundation facilitates day-to-day engagement activities.

R&D, manufacturing, and other commercial clients

A key account management system provides clients with a dedicated company contact.

Regular interaction occurs through the client account team and project teams, with the frequency of communication tailored to the project’s specific requirements.

Each dedicated center has a management team which has responsibility for organizing projects and communicating with clients. The nature of the engagement is established as a component of the contract in each case.

Vendors

The Strategic Sourcing team has oversight of all vendors within the procurement process.

Category managers serve as the initial point of contact for vendors, assisting in contract formulation and managing any concerns or feedback throughout the contract execution.

Local and national authorities

Interaction with authorities can occur through direct engagement with local authorities or involvement in an industry body at the national level.

The Company engages as needed with local authorities through teams such as Health and Safety, Human Resources, and Legal. Additionally, the Company actively participates in industry bodies to collaborate with government departments on relevant industry developments.

Media

Corporate Communications manages all communication with the media either directly or through a specialized consultancy.

Quarterly business briefings are conducted for business media interested in covering financial results. Engaging with trade media individually throughout the quarter offers a chance to highlight scientific accomplishments. During the year, the Company hosted 2 on-site media visits on the Bangalore campus.

Employees

Employees have multiple avenues to connect with colleagues and managers, such as quarterly town halls, COO weekly coffee chats, and additional town hall sessions. For personal support, employees can reach out to the Human Resources (HR) team directly or utilize the HR chatbot. An annual all employee survey provides an independent channel for employee feedback.

Before each town hall, employees are encouraged to submit questions, which are addressed either during the town hall itself or subsequently on the intranet. Managers are responsible for maintaining regular engagement with their team members and conducting both mid-year and full-year performance reviews for each team member. In cases of personal workplace challenges, the HR team offers assistance and support as required.

Investors/ shareholders

The Investor Relations team organizes meetings with analysts and investors throughout the year. Shareholders have the opportunity to interact with the Company through the Company Secretary at any time and during the Annual General Meeting.

Quarterly briefings, led by the MD & CEO and CFO, are conducted for analysts and investors. Investors have the flexibility to request meetings with the Company at any time. A comprehensive report of all meetings is submitted quarterly to the Stakeholder Relationship and ESG Committee.

In the virtual Annual General Meeting held in July 2022, shareholders had the opportunity to directly pose questions to the Chairperson and other Board members.

Quality stakeholders

Engagement with these stakeholders typically occurs within the context of a virtual or physical audit of company operations.

The Chief Quality Officer takes charge of the engagements with all drug regulatory authorities on behalf of the Company. This engagement is structured based on the specific requirements of the respective regulator.

27 GRI 2-29